Navidea Biopharmaceuticals (NYSE:NAVB) announced today that it appointed two new members to its board of directors.
Thomas Forest Farb-Horch and Agnieszka Winkler joined Dublin, Ohio-based Navidea’s board, effective Oct. 7, each with a three-year term ending concurrently with the company’s 2024 annual stockholders’ meeting.
Get the full story at our sister site, Drug Delivery Business News.
Navidea Biopharmaceuticals (NYSE:NAVB) announced today that it made a number of changes on its board of directors.
Dublin, Ohio-based Navidea ‘s chair of the board and director S. Kathryn Rouan, along with director Claudine Bruck, retired from those positions, effective immediately.
Get the full story at our sister site, Drug Delivery Business News.
Navidea Biopharmaceuticals (NYSE:NAVB) announced today that it received a patent for its dextran-based drug delivery vehicles.
The U.S. Patent and Trademark Office (USPTO) issued U.S. patent 11,007,272 entitled “Compounds and Methods for Diagnosis and Treatment of Viral Infections,” with protection to October 7, 2037, according to a news release.
Get the full story at our sister site, Drug Delivery Business News.